PREVENTION OF FETAL GROWTH RETARDATION

Fetal growth restriction (FGR) has been a frequently encountered pathology in obstetrics and affects 5-10% of pregnancies. It has been one of the three main causes of perinatal deaths, after premature births and fetal malformations. In approximately one third of cases with FGR, cause or pathology was not found, which made it difficult to prevent or treat them effectively. Mostly, FGR was a consequence of insufficiency of uteroplacental circulation, placental and fetoplacental function. The term SGA (small for gestational age) has to do with constitutional growth rates and the statistical determination within which the newborn is considered smaller for gestational age. Whereas the term FGR (fetal growth retardation) refers to delayed growth below the 10th percentile as a pathological phenomenon. The current management of FGR consists of fetal surveillance to detect a decline in the baby’s health and deliver when this can be safely done. Therefor Doppler ultrasound was considered the chosen technique. The use of low-dose aspirin for preventing FGR and preeclampsia (PE) has been one of the most important research topics for the last 10 years. Several national protocols recommend the treatment with low-dose aspirin (100-150mg daily) for high-risk pregnancies, starting around 12-16 weeks of gestation. It favors placentation by its proangiogenic, antithrombotic and anti-inflammatory effects.